Abstract
In year one of the COVID-19 epidemic, the incidence of infection for US carceral populations was 5.5-fold higher than that in the community. Prior to the rapid roll out of a comprehensive jail surveillance program of Wastewater-Based Surveillance (WBS) and individual testing for SARS-CoV-2, we sought the perspectives of formerly incarcerated individuals regarding mitigation strategies against COVID-19 to inform acceptability of the new program. In focus groups, participants discussed barriers to their receiving COVID-19 testing and vaccination. We introduced WBS and individual nasal self-testing, then queried if wastewater testing to improve surveillance of emerging outbreaks before case numbers surged, and specimen self-collection, would be valued. The participants’ input gives insight into ways to improve the delivery of COVID-19 interventions. Hearing the voices of those with lived experiences of incarceration is critical to understanding their views on infection control strategies and supports including justice-involved individuals in decision-making processes regarding jail-based interventions.
Competing Interest Statement
Ms. Gonzalez-Montalvo Mr. Dickson Ms. Saber Ms Boehm and Dr. Phillips declare no competing interests. Dr. Akiyama reports that in the past 5 years he has received grant/project funding through his university from Gilead Sciences and Abbvie. Dr. Spaulding in the past 5 years has received grant/project funding through her university from: Gilead Sciences Viral Solutions Cellex The National Institutes of Health The California Department of Corrections Rehabilitation and Health through Walls She has received direct funding from the National Sheriffs Association and Harris County (Texas). She has received test kits from bioLytical Laboratories through her university for a research project. She has formerly been employed in a part-time capacity by Wellpath and Naphcare.
Funding Statement
This project was funded by the Bill and Melinda Gates Foundation (INV035562)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Emory University IRB approved the study protocol Study # 003291. Participants provided written consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Yes - all data are fully available without restriction
